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reconstructed γ-test failure rates of all experiments. The 
reconstructed γ-test failure rates were in excellent agreement with 
the measurements for both the transient dose (left) and the final 
accumulated dose (right). 
Conclusions: A simple time-resolved dose delivery reconstruction 
model was created and its ability to predict dose delivery errors was 
validated experimentally for VMAT treatments with and without DMLC 
tracking. The time-resolved reconstruction allows temporal and 
spatial pinpointing of errors in the dose delivered to moving targets. 
With an online implementation, it may be used for treatment 
intervention in case of erroneous dose evolvement in tracking and 
non-tracking treatments.  
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Purpose/Objective: A convolution-based dose reconstruction 
including intra-fraction residual tumor motion to evaluate dose 
coverage of the gross target volume (GTV) after tumour tracking.  
Materials and Methods: 7 patients were treated with dynamic tumor 
tracking (DTT) on the Vero SBRT system (2 NSCLC and 5 liver/lung 
oligometastases).  
For NSCLC, dose was prescribed to the 95% isodose on the PTV 
perifery, while for lung/liver metastases the dose was prescribed to 
the 80% isodose on the PTV perifery with an intend to boost 60% of the 
GTV to obtain a BED > 100. 
The stable exhale phase of the 4DCT was selected for target 
delineation and DTT treatment planning. An isotropic margin of 5 mm 
was added to the GTV volume to accomodate targeting uncertainty. 
The static dose was calculated with iPlan XVMC. 
DTT on Vero SBRT was performed by a correlation model between skin 
markers and the internal target position. During DTT, the gimballed 
linac compensated for beams-eye view (BEV) target motion while 
ignoring target motion parallel to the beam central-axis (CAX). The 
prediction of the correlation model for the target position was 
verified by 0.5 Hz orthogonal X-ray imaging.  
After DTT treatment, 95th percentiles of respectively tracking errors 
(TE) in the BEV (E95BEV) and 3D displacement of target centroid around 
the tracking beam isocenter (E953D) were calculated. The tumour 
positions were reconstructed from orthogonal imaging, while the 
tracking isocenter was retreived from the gimbals position log file. 
A convolution of the static dose with the 3D probability density 
function (PDF), based on E953D, was performed to reconstruct the 
delivered dose under influence of DTT (see figure 1). The 
reconstructed DTT dose to the GTVDT was compared with the static 
planned dose GTVp by D99 and D60. 
 
  
Results: An overview of the E95BEV and E953D TE and GTV coverage is 
given in table 1. Overall, an average E95BEV of 3.5 mm and E953D of 5.6 
mm was found.  
The planned prescription dose to the PTV perifery resulted in a 
sufficient coverage (D99) of the GTV after convolution for 6 out of 7 
patients. For case 4, an underdosage of 5% to the GTV perifery was 
observed. On average, a dose loss of 7% to the GTV perifery was 
observed with respect to the planned dose intend. A boost to 60% of 
the target volume was maintained in all cases. 
In the current convolution approach, tracking errors in the BEV and 
tumor motion parallel to the CAX were considered to have an equal 
influence on the dose distribution. In reality, a photon dose 
distribution is considered more robust for target motion parallel to 
the CAX. Therefore, the current convolution possibly overestimates 
the influence of total 3D target motion around the isocenter during 
DTT, especially for dose reconstruction with large AP tumor motion, 
like case 4 of our study.  
To further improve DTT dose reconstruction, a more moderate 
handling of CAX target motion is needed during static dose 
convolution.  
 
  
Conclusions: An adequate target dose coverage was obtained after 
dose reconstruction for DTT on a gimballed linac. 
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Purpose/Objective: Respiratory motion monitoring is essential for 
gating or tracking based radiotherapy. A low-cost alternative to 
existing solutions is the Kinect surface sensor from Microsoft. The 
purpose of this study was to develop a reliable non-contact respiratory 
motion monitoring system using the Kinect. The system was calibrated 
with a 4D cone-beam CT (CBCT) acquired before treatment. 
Materials and Methods: The Kinect was mounted on the ceiling of one 
treatment room 2 meters away from the patient's breast surface. 
Depth images were captured at a rate of 30 Hz during the acquisition 
of a 4D cone-beam CT (CBCT) before treatment. The 4D CBCT is part 
of our clinical practice. The torso was segmented using the human 
body segmentation toolkit from the Microsoft Kinect SDK. We used a 
respiratory signal extraction algorithm (1) to detect local respiratory 
motion (Fig 1a). This algorithm uses a modified principal component 
analysis (PCA) on the depth values. The result is a set of components 
that indicate regions of motion. Respiratory signals from each 
combination of dominant components were next correlated with the 
respiratory signal extracted from the projection images of the 4D 
CBCT. The latter were extracted using the 'Amsterdam shroud' method 
(2). The components with the highest correlation were selected. 
The method was tested on 125 datasets of 11 lung cancer patients.  
Results: A single principal component was sufficient in 87.5% of the 
fractions to achieve a the highest correlation with the respiration 
signal from 'the Amsterdam Shroud'. The remaining 12.5% used two 
components. The average correlation coefficient between the motion 
monitoring system and respiratory signal from 4D CBCT used for 
calibration was 0.87 (range: 0.80 to 0.95). The largest source of 
limited correlation were short term phase shifts in the respiratory 
motion (Fig 1b). 
Conclusions: A contact-less respiratory motion system based on Kinect 
was developed to model respiratory motion. By calibrating the system 
to 4D-CBCT for each patient, a highly reliable extracted signal was 
obtained. 
(1) Wasza et al. 2012 Sparse Principal Axes Statistical Surface 
Deformation Models for Respiration Analysis and Classification 
Bildverarbeitung für die Medizin 2012 
(2) Zijp et al. 2004 Extraction of the respiratory signal from sequential 
thorax cone-beam X-ray images ICCR 2004  
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 Figure 1: Areas with distinguishable respiratory motion (white) on the 
patient surface (a). After calibration, motion derived from the body 
surface highly correlates with the Amsterdam Shroud (b) 
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Purpose/Objective: We studied the effect of a higher dose on tumor 
control for localized prostate cancer in a randomized trial with a 
median follow-up of 110 months. 
Materials and Methods: Patients with T1b-T4 prostate cancer were 
included in the period 1997-2003 (n=664) and randomized between 78 
Gy (n=333) and 68 Gy (n=331). Primary endpoint was biochemical 
and/or clinical failure (BCF) according the guidelines of the American 
Society for Therapeutic Radiology and Oncology (ASTRO) (3 
consecutive rises). Secondary endpoints were BCF using the Phoenix 
guidelines (nadir plus 2 µg/L), clinical failure (CF), local failure (LF), 
prostate cancer related death (PCRD), and overall survival (OS). 
Explorative subgroup analyses were performed. 
Results: Estimated freedom from BCF at 10 years according ASTRO 
was 45.9 % and 38.4 % for 78 Gy and 68 Gy, respectively (Log Rank, 
p=0.025). Freedom from BCF according Phoenix definition (Table) was 
superior in the 78 Gy arm as well (p=0.046). CF and OS were similar in 
both arms (Table). LF as a first event was significantly less observed in 
the 78 Gy arm (14 versus 27 events, p=0.036, Figure). For progression 
outside the prostate, i.e. documented regional or distant failure, we 
found more first events in the 78 Gy arm, which was not significant 
(59 versus 43 events, p=0.14). At the current update, 205 patients 
were deceased (104 in the 78 Gy arm), including 88 patients with 
PCRD (44 cases in both arms). Subgroup analysis for BCF showed a 
greater benefit for patients with PSA ≥ 10 ug/L compared to <10 ug/L 
(p<0.01 for heterogeneity). Within the subgroup PSA ≥ 10 ug/L, 
estimated freedom from BCF at 10 years (ASTRO) was 41.7 % for the 
78 Gy arm and 30.0 % for the 68 Gy arm (p=0.008). For the subgroup 
PSA < 10 ug/L, these numbers were 54.4 % and 52.6 %, respectively 
(p=0.9). 
 
 
Figure. Kaplan Meier for local failure as a first event (p=0.036) 
 
  
Conclusions: For the first time, a significant difference in LF is 
demonstrated in a randomized trial. However, despite significant 
differences in BCF and LF, no significant differences in CF and OS 
were observed after a median follow-up of 110 months. More follow-
up is needed to identify possible effects for these endpoints. Probably 
only subgroups of the trial population truly benefit from a higher local 
dose in terms of prolonged OS.  
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Purpose/Objective: Bone metastases from renal cell carcinoma (RCC) 
are common and often less responsive to palliative radiotherapy (RT) 
than metastases from other tumors. Sorafenib is a multi-targeted 
tyrosine-kinase inhibitor that improves progression-free survival in 
metastatic RCC. There is pre-clinical evidence to indicate that 
sorafenib also improves the effectiveness of RT. The purpose of this 
study was to examine the efficacy and toxicity of sorafenib in patients 
with RCC receiving palliative RT for painful bone metastases. 
Materials and Methods: Twelve patients with RCC and bone 
metastases were accrued to a phase I/II prospective study of RT and 
sorafenib. An index lesion was identified in each patient and treated 
to a dose of 30 Gy in 10 daily fractions. Sorafenib 200 mg or 400 mg 
per day was administered beginning one week before RT until at least 
nine weeks after RT. Patients who responded to sorafenib were 
eligible to continue beyond 12 weeks. Pain scores were evaluated 
using the Brief Pain Inventory (BPI). 18F-FDG PET imaging was 
performed at baseline (prior to any treatment) and four weeks after 
treatment to assess metabolic response. Standardized uptake values 
